Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
// Emanuela Palmerini 1 , Claudio Agostinelli 2 , Piero Picci 1 , Stefano Pileri 3, 4 , Teresa Marafioti 5 , Pier-Luigi Lollini 6 , Katia Scotlandi 1 , Alessandra Longhi 1 , Maria Serena Benassi 1 and Stefano Ferrari 1 1 Chemotherapy Unit, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy 2 Haematopathology Unit, Policlinico S. Orsola-Malpighi, Bologna, Italy 3 Haematopathology Unit, European Institute of Oncology, Milan, Italy 4 Bologna University School of Medicine, Bologna, Italy 5 University College London Cancer Institute, London, United Kingdom 6 Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy Correspondence to: Emanuela Palmerini, email: emanuela.palmerini3@unibo.it Keywords: osteosarcoma; PD-1; PD-L1; CD8; tumor microenvironment Received: July 19, 2017 Accepted: November 15, 2017 Published: December 04, 2017 ABSTRACT Background: We hypothesized that immune-infiltrates were associated with superior survival, and examined a primary osteosarcoma tissue microarrays (TMAs) to test this hypothesis. Methods: 129 patients (pts) with localized osteosarcoma treated within protocol ISG-OS1 were included in the study. Clinical characteristics, expression of CD8, CD3, FOXP3, CD20, CD68/CD163 (tumor associated macrophage, TAM), Tia-1 (cytotoxic T cell), CD303 (plasmacytoid dendritic cells: pDC), Arginase-1 (myeloid derived suppressor cells: MDSC), PD-1 on immune-cells (IC), and PD-L1 on tumoral cells (TC) and IC were analysed and correlated with outcome. Results: Most of the cases presented tumor infiltrating lymphocytes (TILs) (CD3+ 90%; CD8+ 86%). Tia-1 was detected in 73% of the samples. PD-L1 expression was found in 14% patients in IC and 0% in TC; 22% showed PD-1 expression in IC. With a median follow-up of 8 years (range 1-13), the 5-year overall survival (5-year OS) was 74% (95% CI 64-85). Univariate analysis showed better 5-year OS for: a) pts with a good histologic response to neoadjuvant chemotherapy (p = 0.0001); b) pts with CD8/Tia1 tumoral infiltrates (p = 0.002); c) pts with normal alkaline phosphatas (sALP) (p = 0.04). After multivariate analysis, histologic response (p = 0.007) and CD8/Tia1 infiltration (p = 0.01) were independently correlated with survival. In the subset of pts with CD8+ infiltrate, worse (p 0.02) OS was observed for PD-L1(IC)+ cases. Conclusions: Our findings support the hypothesis that CD8/Tia1 infiltrate in tumor microenvironment at diagnosis confers superior survival for pts with localized osteosarcoma, while PD-L1 expression is associated with worse survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 1×
“The first study demonstrating the association between CD8 infiltrate and cancer specific survival was published in 2001 [18], and similar findings were subsequently confirmed among many histotypes [19, 20].”
ResultMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · cited 2×
“PD-L1 is expressed also by several tumors [3].”
BackgroundTaube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752 · cited 1×
“Of interest, mifamurtide, a modulator of innate immunity, which increases a wide variety of immunomodulatory molecules [15] and favours CD8 and NK cell activation [30], has been approved by EMA for the treatment of patients with localized high-grade osteosarcoma based on the results of a randomized trial [31].”
BackgroundBuddingh, E. P., Kuijjer, M. L., Duim, R. A. J., Bürger, H., Agelopoulos, K., Myklebost, O., Serra, M., Mertens, F., Hogendoorn, P. C. W., Lankester, A. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2047 · Cited by 508 · cited 2×
“This might be explained by different statistical analysis design and different stages of patients included [13, 14].”
BackgroundKoirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267
Kleinerman, E. S., Jia, S. F., Griffin, J., Seibel, N. L., Benjamin, R. S., & Jaffe, N. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1310 · Cited by 157
Sundara, Y. T., Kostine, M., Cleven, A. H. G., Bovée, J. V. M. G., Schilham, M. W., & Cleton-Jansen, A.-M. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1925-3 · Cited by 111
Cited by
Sarcoma treatment in the era of molecular medicine
Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Boye, K., Longhi, A., Guren, T., Lorenz, S., Næss, S., Pierini, M., Taksdal, I., Lobmaier, I., Cesari, M., Paioli, A., et al. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-02876-w · Cited by 112
“In our study, a strong PD-L1 expression was observed in a pretreatment biopsy from the patient with a mixed response, whereas all other samples were PD-L1 negative, in agreement with previous studies [18].”
ResultSelf-citationGD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Park, J. A., & Cheung, N.-K. V. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01012-y · Cited by 88
Genomics and the Immune Landscape of Osteosarcoma
Wu, C.-C., & Livingston, J. A. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43085-6_2 · Cited by 58
Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma
Liu, Z., Wang, H., Hu, C., Wu, C., Wang, J., Hu, F., Fu, Y., Wen, J., & Zhang, W. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03449-6 · Cited by 45
Metadata
- Authors
- Palmerini, E., Agostinelli, C., Picci, P., Pileri, S., Marafioti, T., Lollini, P.-L., Scotlandi, K., Longhi, A., Benassi, M. S., & Ferrari, S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-12-04
- Volume
- 8
- Issue
- 67
- Pages
- 111836-111846
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2774372124
- Cited by
- 65
- References
- 10
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. https://app.cochat.ai/papers/10.18632/oncotarget.22912
- The paper
- Palmerini, E., Agostinelli, C., Picci, P., Pileri, S., Marafioti, T., Lollini, P.-L., Scotlandi, K., Longhi, A., Benassi, M. S., & Ferrari, S. (2017). Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. Oncotarget. https://doi.org/10.18632/oncotarget.22912
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.